Key points are not available for this paper at this time.
The NCCN Guidelines for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer and other urinary tract cancers (upper tract tumors, urothelial carcinoma of the prostate, primary carcinoma of the urethra). These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines regarding the treatment of non-muscle-invasive bladder cancer, including how to treat in the event of a bacillus Calmette-Guérin (BCG) shortage; new roles for immune checkpoint inhibitors in non-muscle invasive, muscle-invasive, and metastatic bladder cancer; and the addition of antibody-drug conjugates for metastatic bladder cancer.
Building similarity graph...
Analyzing shared references across papers
Loading...
Thomas W. Flaig
Philippe E. Spiess
Michael Abern
Journal of the National Comprehensive Cancer Network
University of Michigan
University of Pennsylvania
Memorial Sloan Kettering Cancer Center
Building similarity graph...
Analyzing shared references across papers
Loading...
Flaig et al. (Mon,) studied this question.
www.synapsesocial.com/papers/69fd0a23f35524303e26ff47 — DOI: https://doi.org/10.6004/jnccn.2022.0041
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: